Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GE HealthCare TechnologiesGEHC -0.15%72 3-Year EBITDA Growth Rate is 5.10% as of Jun. 2026, which is 89% above its 10-year median of 2.70. GuruFocus rates GEHC with a GF Score™ of 72/100 and a GF Value™ of $84.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 692 Medical Devices & Instruments companies, GE HealthCare Technologies ranks worse than 55.92% on this metric.
During the past 12 months, GE HealthCare Technologies's average EBITDA Per Share Growth Rate was -3.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 1.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of GE HealthCare Technologies was 5.10% per year. The lowest was 0.80% per year. And the median was 2.70% per year.
GE HealthCare Technologies (NAS:GEHC) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
GE HealthCare Technologies 3-Year EBITDA Growth Rate Related Terms
GEHC vs DXCM, STE, ZBH: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, GE HealthCare Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GE HealthCare Technologies 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GE HealthCare Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where GE HealthCare Technologies's 3-Year EBITDA Growth Rate falls into.
GE HealthCare Technologies 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.10% mean?
GE HealthCare Technologies (GEHC) has a 3-Year EBITDA Growth Rate of 5.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GE HealthCare Technologies and its competitors. This is 89% above median its historical median of 2.70. Over the past decade, GE HealthCare Technologies' 3-Year EBITDA Growth Rate has ranged from 0.80 to 5.10. According to the industry distribution chart, GE HealthCare Technologies ranks #387 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 55.9%.
Is GE HealthCare Technologies' 3-Year EBITDA Growth Rate too high?
GE HealthCare Technologies' current 3-Year EBITDA Growth Rate of 5.10% is 89% above median its 10-year median of 2.70. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 5.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. GE HealthCare Technologies' value of 5.10% is 37.8% below this industry median. Based on the distribution chart, GE HealthCare Technologies ranks #387 out of 692 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, GE HealthCare Technologies has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GE HealthCare Technologies' 3-Year EBITDA Growth Rate compare to DXCM and STE?
According to the Medical Devices & Instruments industry distribution chart, GE HealthCare Technologies ranks #387 out of 692 companies for 3-Year EBITDA Growth Rate. This places GE HealthCare Technologies in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. GE HealthCare Technologies' value of 5.10% is 37.8% below this benchmark. Historically, GE HealthCare Technologies' own 3-Year EBITDA Growth Rate has ranged from 0.80 to 5.10 over the past decade. While the company's 10-year median is 2.70 vs. the industry median of 8.20, GE HealthCare Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GE HealthCare Technologies's current 3-Year EBITDA Growth Rate of 5.10% is 37.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GE HealthCare Technologies and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GE HealthCare Technologies's current 3-Year EBITDA Growth Rate is 5.10%, which is 89% above median its own 10-year median of 2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GE HealthCare Technologies stock overvalued right now?
Based on GuruFocus' analysis, GE HealthCare Technologies (GEHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $84.16, compared to a current price of $73.69 — trading 12.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.10%, which is 89% above median its 10-year median of 2.70 and 37.8% below the Medical Devices & Instruments industry median of 8.20. GE HealthCare Technologies' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For GE HealthCare Technologies (GEHC), the current 3-Year EBITDA Growth Rate is 5.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GE HealthCare Technologies (GEHC) Overvalued in 2026?
Based on GuruFocus' analysis, GE HealthCare Technologies stock appears to be undervalued.
The current stock price of $73.69 is trading 12.4% below its estimated GF Value™ of $84.16.
GuruFocus considers GE HealthCare Technologies to be Modestly Undervalued.
Key valuation signals for GEHC:
3-Year EBITDA Growth Rate: 5.10% (89% above median its 10-year median of 2.70)
GF Value™: $84.16 vs. price of $73.69 (12.4% below fair value)
Industry Position: 37.8% below the Medical Devices & Instruments median (#387 of 692)
No single metric tells the full story. See the GEHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
72GF Score
Get the complete analysis for GEHC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GEHC has been successfully added to your 
